ISSN: 1308-5727 | E-ISSN: 1308-5735
Volume: 14 Issue: 2 Year: 2022

Abstracting & Indexing
Turkish Society for Pediatric Endocrinology and Diabetes
Weight Loss during Topiramate Treatment in a Severely Obese Adolescent with Congenital Adrenal Hyperplasia and Migraine [J Clin Res Pediatr Endocrinol]
J Clin Res Pediatr Endocrinol. Ahead of Print: JCRPE-92486 | DOI: 10.4274/jcrpe.galenos.2021.2020.0310

Weight Loss during Topiramate Treatment in a Severely Obese Adolescent with Congenital Adrenal Hyperplasia and Migraine

Amy Seagroves1, Heather M. Ross1, Alaina P. Vidmar1, Mitchell E. Geffner1, William S. Kim1, Darryl Hwang2, Claudia Borzutzky4, Nicole R. Fraga1, Mimi S. Kim3
1Center for Endocrinology, Diabetes and Metabolism, Children’s Hospital Los Angeles
2Keck School of Medicine of University of Southern California
3The Saban Research Institute
4Division of Adolescent and Young Adult Medicine, Children’s Hospital Los Angeles

Youth with classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency exhibit an increased prevalence of obesity, early adiposity rebound, and increased abdominal adiposity compared to unaffected youth. Current obesity management in CAH largely focuses on lifestyle modifications. There is evidence that topiramate therapy is effective in reducing BMI, as well as visceral adipose tissue, in unaffected adolescents with exogenous obesity. However, little is known about the efficacy of topiramate in patients with classical CAH. We report a 17-year-old female with severe obesity and salt-wasting CAH due to 21-hydroxylase deficiency, who demonstrated reductions in BMI, as well as abdominal visceral and subcutaneous adipose tissue on topiramate therapy. The patient was diagnosed with classical CAH as a newborn with a 17-hydroxyprogesterone 11,000 ng/dL. She had a BMI > 95th percentile at 3 years old, followed by unremitting obesity. At 17 years old, she was started on topiramate to treat chronic migraines. Following three years of topiramate therapy, her BMI z-score decreased from +2.6 to +2.1. After four years of therapy, her waist circumference decreased from 110 to 101 cm, abdominal visceral adipose tissue decreased substantially by 34.2%, and abdominal subcutaneous adipose tissue decreased by 25.6%. Topiramate therapy was associated with effective weight loss and reduced central adiposity in an adolescent with classical CAH and severe obesity, without side effects. Further study is warranted regarding topiramate therapy in obese youth with classical CAH and increased central adiposity, who are at higher risk for significant morbidity.

Keywords: congenital adrenal hyperplasia, topiramate, obesity, body composition, body fat percentage, adolescent, 21-Hydroxylase deficiency

Corresponding Author: Mimi S. Kim, United States of America
Manuscript Language: English
LookUs & Online Makale